
WHAT IS CLAIMED IS:

[Claim 1]. A compound of Formula I:



(Iva)

or a pharmaceutically acceptable salt thereof, wherein

R^1 is heterocycloalkyl having 5 to 6 ring members and 1 to 2 heteroatoms each N, phenyl or a heteroaryl having 5 to 6 ring members and 1 to 2 heteroatoms each N or S, each substituted with 1 to 3 R^{1a} groups;

each R^{1a} is independently hydrogen, C_{1-3} alkyl, C_{1-3} deuteroalkyl, C_{1-3} alkoxy, C_{1-3} hydroxyalkyl, halogen, C_{1-3} haloalkyl, oxo, -CN, C_{3-6} cycloalkyl, or heterocycloalkyl having 3 to 5 ring members and 1 to 2 heteroatoms each N or O;

A^1, A^2, A^3 and A^4 are each independently $=CR^2$- or =N-;

each R^2 is independently hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, hydroxy or -CN;

each R^{3a} is independently hydrogen, -OH, or oxo316yridine316ntly;

R^{3b} is C_{1-6} alkyl, C_{2-6} alkynyl, C_{2-6} alkoxyalkyl, C_{2-6} alkynyl-C_{3-6} cycloalkyl, C_{1-6} alkyl-C_{6-12} aryl, C_{2-6} alkenyl-C_{6-12} aryl, C_{2-6} alkynyl-C_{6-12} aryl, C_{1-6} alkyl-O-C_{6-12} aryl, C_{1-6} alkoxyalkyl-C_{6-12} aryl, -C(O)-C_{6-12} aryl, or C_{1-6} alkyl-heteroaryl, wherein each heteroaryl has 5 to 10 ring members and 1 to 3 heteroatoms each independently N, O or S, and wherein each aryl and heteroaryl is substituted with 1 to 3 R^{3b3} groups;

each R^{3b3} is hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, halogen, or C_{1-6} haloalkyl;

R^4 is C_{1-6} alkyl, C_{1-6} haloalkyl, -CN, C_{3-8} cycloalkyl, 3 to 8 membered heterocycloalkyl having 1 to 3 heteroatoms each independently N, O or S, C_{6-12} aryl, or 5 to 10 membered heteroaryl having 1 to 5 heteroatoms each independently N, O or S, wherein the cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each independently substituted with 1 to 5 R^{4a} groups;

each R^{4a} is hydrogen, C_{1-6} alkyl, C_{1-6} deuteroalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, C_{1-6} hydroxyalkyl, halogen, C_{1-6} haloalkyl, -CN, -OH, oxo, $-S(O)_2R^{4b}$, $-S(O)_2N(R^{4b})(R^{4c})$, C_{3-6} cycloalkyl, C_{6-12} aryl, or $-O-C_{6-12}$ aryl, wherein each aryl is optionally substituted with C_{1-6} alkoxy;

each R^{4b} and R^{4c} is hydrogen or C_{1-6} alkyl;

L^1 is absent; and

L^2 is absent, $–CH_2-$, -C(O)-, $-C(O)CH_2-$, $-C(O)CH_2CH_2-$, $-C(O)CH_2O-$, $-C(O)(CH_2)_3O-$, or $-S(O)_2-$.


[Claim 2]. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein


R^1 is piperidine, pyrdin-2-one, phenyl, pyridine, pyrazole, or thiazole, each substituted with 1 to 3 R^{1a} groups; and

each R^{1a} is hydrogen, methyl, ethyl, iso-propyl, $-CD_3$, methoxy, $-CH_2OH$, F, Cl, $-CHF_2$, $-CF_3$, oxo, -CN, cyclopropyl, or oxetane.


[Claim 3]. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein

R^1 is





[Claim 4]. The compound any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, having the structure:



(IVb) .


[Claim 5]. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein

A^1, A^2, A^3 and A^4 are each independently $=CR^2$- or =N-; and

each R^2 is independently hydrogen, $C_{1\text{-}4}$ alkyl, $C_{1\text{-}4}$ alkoxy, halogen, or –CN.


[Claim 6]. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein A^1, A^2, A^3 and A^4 are each independently =CH-, =C(Me)-, =C(Et)-, =C(iPr)-, =C(OMe)-, =C(F)-, =C(Cl)-, =C(CN)- or =N-.

[Claim 7]. The compound any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, having the structure:



(IVc) .

[Claim 8]. The compound any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, having the structure:



(IVd) .

[Claim 9]. The compound of any one of claims 1to 8, or a pharmaceutically acceptable salt thereof, wherein


R^{3b} is C_{1-3} alkyl, C_{2-3} alkynyl, C_{2-3} alkoxyalkyl, C_{2-3} alkynyl-C_{3-6} cycloalkyl, C_{1-3} alkyl-C_{6-12} aryl, C_{2-3} alkenyl-C_{6-12} aryl, C_{2-3} alkynyl-C_{6-12} aryl, C_{1-3} alkyl-O-C_{6-12} aryl, C_{1-3} alkoxyalkyl-C_{6-12} aryl, -C(O)-C_{6-12} aryl, or C_{1-3} alkyl-heteroaryl, wherein each heteroaryl has 5 to 10 ring members and 1 to 3 heteroatoms each independently N, O or S, and wherein each aryl and heteroaryl is substituted with 1 to 3 R^{3b3} groups; and

each R^{3b3} is hydrogen, C_{1-3} alkyl, C_{1-3} hydroxyalkyl, halogen, or C_{1-3} haloalkyl.


[Claim 10]. The compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R^{3b3} is hydrogen, methyl, -CH_2OH, F, -CHF_2, or -CF_3.

[Claim 11]. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein

R^{3b} is ethyl, -$CH_2C{\equiv}CH$, -CH_2OMe,




[Claim 12]. The compound any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, having the structure:



(IVe) .

[Claim 13]. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein L^2 is -C(O)- or -$S(O)_2$-.

[Claim 14]. The compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, having the structure:



(IVf) .

[Claim 15]. The compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein

R^4 is C_{1-3} alkyl, C_{1-3} haloalkyl, -CN, C_{3-6} cycloalkyl, 4 to 6 membered heterocycloalkyl having 1 heteroatoms each N or O, C_{6-12} aryl, or 5 to 10 membered heteroaryl having 1 to 4 heteroatoms each independently N, O or S, wherein the cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each independently substituted with 1 to 2 R^{4a} groups;

each R^{4a} is hydrogen, C_{1-3} alkyl, C_{1-3} deuteroalkyl, C_{1-3} alkoxy, C_{2-3} alkoxyalkyl, C_{1-3} hydroxyalkyl, halogen, C_{1-3} haloalkyl, -CN, -OH, oxo, -$S(O)_2R^{4b}$, -$S(O)_2N(R^{4b})(R^{4c})$, C_{3-6} cycloalkyl, C_{6-12} aryl, or -O-C_{6-12} aryl, wherein each aryl is optionally substituted with C_{1-3} alkoxy; and

each R^{4b} and R^{4c} is hydrogen or C_{1-3} alkyl.


[Claim 16]. The compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein


R^4 is methyl, ethyl, -CF_2CH_3, -CN, cyclopropyl, cyclobutyl, piperidinyl, tetrahydropyranyl, pyrimidine-dione, phenyl, pyridinyl, pyridin-2-one, quinolinyl, pyrazolyl, imidazolyl, pyridazinyl, pyrimidinyl, indazolyl, triazolyl, pyrazolo-pyrimidine, tetrazolyl, oxazolyl, isoxazolyl, benzoisoxazolyl, oxadiazolyl, thiophenyl, benzothiophenyl, or thiazolyl; and

each R^{4a} is hydrogen, methyl, ethyl, n-propyl, iso-butyl, -CD_3, methoxy, -$CH_2CH_2OCH_3$, hydroxymethyl, F, Cl, -CHF_2, –CF_3, -CH_2CF_3, -CN, -OH, oxo, -$S(O)_2Me$, -$S(O)_2NHMe$, cyclobutyl, 2-methoxyphenyl or –OPh.

[Claim 17]. The compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, wherein


R^4 is methyl, -CF_2CH_3, -CN,










[Claim 18]. The compound of any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, wherein

R^1 is








, or ;



A^1 is =CH-or =N-;


A^2 and A^4 are each =CH-;

A^3 is =CH-, =C(Me)-, =C(Et)-, =C(iPr)-, =C(OMe)-, =C(F)-, =C(Cl)-, or =C(CN)-;

each R^{3a} is hydrogen, -OH, or oxo;


R^{3b} is ethyl, -$CH_2C{\equiv}CH$, -CH_2OMe,







L^1 and L^2 together are $–CH_2$-, -C(O)-, -$C(O)CH_2$-, -$C(O)CH_2CH_2$-, -$C(O)CH_2O$-, -$C(O)(CH_2)_3O$-, or -$S(O)_2$-; and


R^4 is methyl, -CF_2CH_3, -CN,






[Claim 19]. The compound of claim 1, or a pharmaceutically acceptable salt thereof, is a compound in Table 1H, Table 1I, Table IJ, Table 1K, Table 2A, Table 2B, Table 2C, Table 2D, Table 2E or Table 2F.

[Claim 20]. The compound of claim 1 or 19, or a pharmaceutically acceptable salt thereof, has the structure:




.

[Claim 21]. The compound of claim 1 or 19, or a pharmaceutically acceptable salt thereof, has the structure:




.

[Claim 22]. The compound of claim 1 or 19, or a pharmaceutically acceptable salt thereof, has the structure:




.


[Claim 23]. The compound of claim 1 or 19, or a pharmaceutically acceptable salt thereof, has the structure:



[Claim 24]. The compound of claim 1 or 19, or a pharmaceutically acceptable salt thereof, has the structure:



[Claim 25]. The compound of claim 1 or 19, or a pharmaceutically acceptable salt thereof, has the structure:



[Claim 26]. A pharmaceutical composition comprising a compound of any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[Claim 27]. Use of a compound of any of claims 1 to 25, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 26 in the

preparation of a medicament for use in treating a disorder or condition, wherein the disorder or condition is selected from the group consisting of amyotrophic lateral sclerosis (ALS), obesity, diabetes, cardiovascular disease, hypertension, Syndrome X, depression, anxiety, glaucoma, neurodegeneration, Alzheimer's disease, Parkinson's disease, Cushing's Syndrome, Cushing Disease, cancer, liver disease, osteoporosis, muscle frailty, a disorder caused by adrenal disease-related cortisol excess, addiction, psychosis, anorexia, cachexia, post-traumatic stress syndrome, post-surgical bone fracture, a GR-related metabolic disorders, major psychotic depression, mild cognitive impairment, dementia, hyperglycemia, a stress disorder, antipsychotic induced weight gain, delirium, cognitive impairment in depressed patients, postpartum psychosis, postpartum depression, and a neurological disorder in a premature infant.

[Claim 28]. A compound of any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 26, for use in treating a disorder or condition through modulating a glucocorticoid receptor.

[Claim 29]. A compound of any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 26, for use in treating a disorder or condition through antagonizing a glucocorticoid receptor.

[Claim 30]. Use of a compound of any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 26, in the manufacture of a medicament for treating a disorder or condition through modulating a glucocorticoid receptor.

[Claim 31]. Use of a compound of any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 26, in the manufacture of a medicament for treating a disorder or condition through antagonizing a glucocorticoid receptor.